BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 4.97 |
| Open | 5.00 |
| Bid | 5.11 x 3100 |
| Ask | 5.12 x 900 |
| Day's Range | 4.98 - 5.17 |
| 52 Week Range | 2.80 - 5.37 |
| Volume | 605,651 |
| Avg. Volume | 666,867 |
| Market Cap | 454.777M |
| Beta (3Y Monthly) | -0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.42 |
- American City Business Journals
From Iqvia to Cree: Execs with ties to Triangle companies inked millions in Q3 stock sales
Once again, top executives with ties to Triangle companies are walking away with millions of dollars in insider stock sales.
- GlobeNewswire
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred.
- GlobeNewswire
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
RALEIGH, N.C., Sept. 17, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- Zacks
BioDelivery (BDSI) Up 8.9% Since Last Earnings Report: Can It Continue?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
RALEIGH, N.C., Aug. 29, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- GlobeNewswire
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
RALEIGH, N.C., Aug. 28, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with.
- Thomson Reuters StreetEvents
Edited Transcript of BDSI earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 BioDelivery Sciences International Inc Earnings Call
Motley FoolBioDelivery Sciences International, Inc. (BDSI) Q2 2019 Earnings Call Transcript
BDSI earnings call for the period ending June 30, 2019.
- Zacks
BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2
BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.
- GlobeNewswire
BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations
BELBUCA® Net Sales Increased 147% versus Prior Year to All-Time High of $24.1 MillionRaises Full-Year BELBUCA Net Sales Expectations to $90 - $93 MillionRaises Full-Year Total.
- Simply Wall St.
How Much Are BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Insiders Taking Off The Table?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Zacks
Will BioDelivery Sciences International (BDSI) Report Negative Earnings Next Week? What You Should Know
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
RALEIGH, N.C., July 30, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic.
- PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioDelivery Sciences International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , July 29, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- TheStreet.com
3 Small-Caps That Look Like Bargains at Current Trading Levels
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .
- GlobeNewswire
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July.
- Zacks
Perrigo Completes Ranir Acquisition, Raises '19 Guidance
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
- Zacks
Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.
- Benzinga
18 Stocks Joining The Russell Indices
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
- Zacks
Zacks.com featured highlights include: BioDelivery, Ciena, United States and Molina
Zacks.com featured highlights include: BioDelivery, Ciena, United States and Molina
- Zacks
Focus on 4 Liquid Picks on the Top Rung for Robust Returns
Here are four top-ranked liquid stocks that investors can cling on to for significant returns.
- Zacks
What Makes BioDelivery (BDSI) a New Strong Buy Stock
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
